- Last Friday, the Office of the United States Trade Representative (USTR) announced the final modifications concerning the statutory review of tariff actions on China. This entails a new tariff rate on medical/surgical gloves, which will be revised to 50% and 100% (effective 2025 and 2026) from 25% effective 2026 as proposed in May.
- - Read this at SGinvestors.io -
- Still OVERWEIGHT on Glove manufacturing sector; Top Picks: Riverstone (SGX:AP4), Hartalega, and Kossan Rubber.
A relief for local players.
- - Read this at SGinvestors.io -
- Recall: In Sep 2019, when the US imposed a 7.5% tariff on China-made products, US gloves import volumes from China fell to just 7% in Jan 2020 from pre-tariff volumes of 14-16%.
Implications for China players.
- Read more at SGinvestors.io.
Above is an excerpt from a report by RHB Securities Research.
Clients of RHB may be the first to access the full PDF report @ https://www.rhbtradesmart.com/.
Oong Chun Sung RHB Securities Research | Singapore Research RHB Invest | https://www.rhbgroup.com/ 2024-09-17
Read also RHB's most recent report:
2025-02-25 Riverstone - Staying The Course; Maintain BUY.
Previous report by RHB:
2025-02-24 Riverstone - Chalks A Solid Close To FY24; Maintain BUY..
Price targets by other brokers at Riverstone Target Prices.
Listing of research reports at Riverstone Analyst Reports.
Relevant links:
Riverstone Share Price History,
Riverstone Announcements,
Riverstone Dividend Payout Dates & Corporate Actions,
Riverstone News
